Why the study?
There has been no definitive tool to simultaneously monitor the antithrombotic effects of antiplatelet and anticoagulant drugs.
Does the Total Thrombus-Formation Analysis System (T-TAS) accurately assess the antithrombotic effects of medications and predict bleeding events in patients with cardiovascular disease?
Does the Total Thrombus-Formation Analysis System (T-TAS) accurately assess the antithrombotic effects of medications and predict bleeding events in patients with cardiovascular disease?
T-TAS provides a quantitative, microchip-based method to monitor the effects of antiplatelet and anticoagulant therapies, potentially predicting bleeding risks during cardiovascular procedures.
Answers are grounded in this paper and cite their sources.
T-TAS may aid bleeding risk assessment in CVD procedures; hypothesis-generating and requires prospective trials before clinical adoption.
inhibitors is prescribed in patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI). Direct oral anticoagulants (DOACs) are widely used for the prevention or treatment of thromboembolism in patients with atrial fibrillation (AF) and venous thromboembolism. However, there has been no definitive tool to simultaneously monitor the antithrombotic effects of these drugs. The Total Thrombus-Formation Analysis System (T-TAS), a microchip-based flow chamber system that mimics in vivo conditions for evaluating whole blood thrombogenicity, was developed for the quantitative analysis of thrombus formation in whole blood specimens. The utility of T-TAS has been evaluated in CAD patients treated with antiplatelet therapies. The T-TAS PL chip area under the flow pressure curve (AUC) accurately assesses primary hemostasis and is sensitive to the therapeutic effects of various antiplatelet therapies. In addition, low AUC results are a significant predictor of periprocedural bleeding events in CAD patients undergoing PCI. The T-TAS AR chip AUC result is useful for assessing the efficacy of DOACs and warfarin in AF patients undergoing catheter ablation, and it is also a potential independent predictor of periprocedural bleeding events and avoidance of thrombosis in patients having undergone total knee arthroplasty. In conclusion, T-TAS is a useful index for evaluating the total antithrombotic effects of combination antithrombotic agents in patients with various cardiovascular diseases.
No takes yet. Share an insight, caveat, or question.
Kaikita et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: